Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
Open Access
- 20 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000590
- https://doi.org/10.1136/jitc-2020-000590
Abstract
Purpose Patients with cancer receiving tumor-reactive humanized monoclonal antibody (mAb) therapy can develop a human antihuman antibody (HAHA) response against the therapeutic mAb. We evaluated for HAHA in patients with neuroblastoma treated in a phase I study of humanized anti-GD2 mAb (immunoglobulin (Ig)G1 isotype), hu14.18K322A (NCT00743496). The pretreatment sera (collected prior to mAb treatment) from 9 of 38 patients contained antitherapeutic antibodies, even though they had no prior mAb exposure. We sought to characterize these pre-existing antitherapeutic antibodies (PATA). Experimental design The PATA+ pretreatment samples were characterized via ELISA; clinical associations with PATA status were evaluated. Results Pretreatment sera from eight of nine PATA+ patients also bound rituximab and demonstrated preferential ELISA reactivity against the Fc portions of hu14.18K322A and rituximab as compared with the Fab portions of these mAbs. These PATA+ sera also recognized dinutuximab (human IgG1 isotype) and mouse IgG2a isotype mAbs, but not a mouse IgG1 isotype or the fully human panitumumab (IgG2 isotype) mAb. Of the 38 treated patients, only 4 patients (all in the PATA+ cohort) demonstrated no disease progression for >2.5 years without receiving further therapy (p=0.002). Conclusions This study demonstrates an association between clinical outcome and the presence of PATA against determinant(s) on the Fc component of the therapeutic mAb, suggesting that the PATA may be playing a role in augmenting mAb-based antitumor effects. Further analyses for the presence of PATA in a larger cohort of patients with relapsed neuroblastoma, analyses of their clinical correlates, identification of their immunological targets, and potential antitumor mechanisms are warranted.Funding Information
- Foundation for the National Institutes of Health (CA032685, CA87025, CA166105, CA197078, GM067386, U)
- American Lebanese Syrian Associated Charities
- Howard Hughes Medical Institute
- Stand Up To Cancer (St. Baldrick’s Pediatric Cancer Dream Team Trans)
- St. Baldrick's Foundation
- Alex's Lemonade Stand Foundation for Childhood Cancer
- NIH Cancer Center Support Grants (CA14520 and CA21765)
- Midwest Athletes Against Childhood Cancer
This publication has 25 references indexed in Scilit:
- Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapyImmunotherapy, 2016
- Dinutuximab: First Global ApprovalDrugs, 2015
- Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent NeuroblastomaJournal of Clinical Oncology, 2014
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaThe New England Journal of Medicine, 2010
- Development trends for human monoclonal antibody therapeuticsNature Reviews Drug Discovery, 2010
- Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodyniaPain, 2010
- Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With NeuroblastomaClinical Cancer Research, 2009
- Human immunoglobulin allotypesmAbs, 2009
- A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastomaCancer, 1997
- Systemic Interleukin-2 Modulates the Anti-Idiotypic Response to Chimeric Anti-GD2 Antibody in Patients with MelanomaJournal of Immunotherapy, 1996